Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells $398,320.37 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,561 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $398,320.37. Following the sale, the chief marketing officer now owns 13,537 shares of the company’s stock, valued at approximately $3,454,236.29. This represents a 10.34 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Pushkal Garg also recently made the following trade(s):

• On Tuesday, February 18th, Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $251.67, for a total value of $389,585.16.
• On Monday, January 27th, Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00.
• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $251.00, for a total value of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $250.98, for a total value of $422,148.36.

Alnylam Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ ALNY opened at $252.49 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The business’s fifty day moving average price is $254.04 and its 200-day moving average price is $263.12. The stock has a market capitalization of $32.69 billion, a PE ratio of -116.36 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.94 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Capital World Investors lifted its position in shares of Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company’s stock valued at $3,906,284,000 after buying an additional 92,101 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock valued at $2,996,296,000 after purchasing an additional 98,303 shares during the period. Capital Research Global Investors raised its stake in shares of Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock valued at $1,639,767,000 after purchasing an additional 1,724,610 shares during the period. Regeneron Pharmaceuticals Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 39.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock valued at $1,031,705,000 after purchasing an additional 1,245,195 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ALNY. Canaccord Genuity Group boosted their price objective on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a report on Tuesday. Raymond James lifted their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, February 14th. Piper Sandler reaffirmed an “overweight” rating and set a $296.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Finally, Sanford C. Bernstein cut their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $299.48.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.